Cross-border biotech deals grow more complex as US targets China investment links

Cross-border biotech deals between China and the United States are becoming more complicated and could face a modest slowdown as Washington steps up efforts to restrict investment and technology transfers, according to industry analysts. “There will be more geopolitical scrutiny